ESMO 2020: Meta-Analysis Summarizes Quality of Life Impact of Immune Checkpoint Inhibitors
Greatest benefit is seen with durvalumab, nivolumab, and pembrolizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.